How To Avoid The Deca Bloat?

**Hot-Rox** · 01-07-2005, 10:18 AM

I am about to start a test cyp / deca cycle. Does anyone have experience with L-Dex or other med to keep bloating to a minimum. And, what doses?

**ace ventura** · 01-07-2005, 10:35 AM

I read everyone is saying nolvadex (10-20 mg/ed) will help on the bloat. It's the estrogen that causes the bloat so you basically want to keep the level down.

**stocky121** · 01-07-2005, 10:44 AM

proviron 50 mg per day will keep the bloat down

**Hot-Rox** · 01-07-2005, 11:53 AM

Anyone out there with a little L-Dex advice or suggestions for elinating bloat?

**bullram** · 01-07-2005, 11:57 AM

letro (femera) keeps you dry as a bone

**tycin** · 01-07-2005, 12:07 PM

femara is the best IMO

***BajanBastard*** · 01-07-2005, 12:12 PM

Letrozole will attack all the angles from bloat to deca gyno.

***asymmetrical1*** · 01-07-2005, 12:27 PM

Originally Posted by Hot-Rox

Anyone out there with a little L-Dex advice or suggestions for elinating bloat?

gona run letro soon....... if you bloat on .25ml l-dex and 10mg nolv/ed, something is wrong

**ManzNumero1** · 01-07-2005, 12:29 PM

can you run letro and clomid at the same time. .

**GetinBig** · 01-07-2005, 12:30 PM

I took .25mg of l-dex and 20mg of nolva and did not bloat while on deca . Never ran the letro though. So can't even help on how much to take..

**Hot-Rox** · 01-07-2005, 02:33 PM

What is the difference between Letro & L-Dex?

Originally Posted by big k.l.g

Letrozole will attack all the angles from bloat to deca gyno.

**yuri76** · 01-07-2005, 03:01 PM

letro worked great for me....I ran it daily at 0.25mg.

**peump** · 01-07-2005, 03:08 PM

http://67.18.108.244//showthread.php?t=125162

this should help you

**peump** · 01-07-2005, 03:08 PM

Originally Posted by Hot-Rox

What is the difference between Letro & L-Dex?

http://67.18.108.244//showthread.php?t=125162

**shrunkennutz116** · 01-07-2005, 03:51 PM

i always thought anti estrogens wouldnt do ne thing for deca bloat maybe i'm wrong ne one kno for sure?

**Property of Steroid.com** · 01-07-2005, 04:23 PM

Originally Posted by MMA

are u sure about that? i thought deca gyno was progesterone/prolactin mediated, and anti-Es had no effect on it? does letro affect progesterone?.

Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.

Berstein L, Maximov S, Gershfeld E, Meshkova I, Gamajunova V, Tsyrlina E, Larionov A, Kovalevskij A, Vasilyev D.

Laboratory Oncoendocrinology, N.N. Petrov Research Institute of Oncology, St. Petersburg 197758, Russia. [email protected]

OBJECTIVE: To investigate the short-term hormonal and clinical effects of the aromatase inhibitor letrozole (Femara) in patients with endometrial cancer. MATERIALS AND METHODS: Ten previously untreated, post-menopausal patients (mean age 59 years) with endometrial cancer, predominantly stage I disease, received letrozole 2.5mg per day for 14 days before surgery. Clinical, sonographic, morphologic, cytologic, and hormonal-metabolic parameters (blood estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), glucose, and cholesterol by radioimmunoassay, enzyme immune assay, or enzyme-colorimetric methods; tumor progesterone receptors by ligand-binding assay; and aromatase activity by 3H-water release assay) were evaluated before and after treatment. RESULTS: Treatment was well-tolerated in all patients. In two patients, pain relief in the lower part of the belly and/or decrease in intensity of uterine discharge was reported. In the three cases, substantial decreases in endometrial M-echo (ultrasound) signal were noted; the mean value of this parameter after treatment was 31.1% lower than before treatment. Blood estradiol concentration decreased by an average of 37.8% after letrozole therapy, and tumor progesterone receptor levels and aromatase activity decreased by 34.4 and 17.5%, respectively. Treatment with letrozole did not influence surgery. CONCLUSIONS: These data show that short-term treatment with letrozole in the neoadjuvant setting resulted in some positive clinical changes. Longer-term and larger-scale trials of neoadjuvant letrozole in endometrial cancer are warranted.

**Property of Steroid.com** · 01-07-2005, 05:02 PM

Join BB4L!!!!

It's old news over there!

**Property of Steroid.com** · 01-07-2005, 05:08 PM

Join BB4L!!!!

It's old news over there!

**Hot-Rox** · 01-07-2005, 06:59 PM

Thanks for the great info! What is the function of L-Dex - and does it compare?

Originally Posted by hooker

Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.

Berstein L, Maximov S, Gershfeld E, Meshkova I, Gamajunova V, Tsyrlina E, Larionov A, Kovalevskij A, Vasilyev D.

Laboratory Oncoendocrinology, N.N. Petrov Research Institute of Oncology, St. Petersburg 197758, Russia. [email protected]

OBJECTIVE: To investigate the short-term hormonal and clinical effects of the aromatase inhibitor letrozole (Femara) in patients with endometrial cancer. MATERIALS AND METHODS: Ten previously untreated, post-menopausal patients (mean age 59 years) with endometrial cancer, predominantly stage I disease, received letrozole 2.5mg per day for 14 days before surgery. Clinical, sonographic, morphologic, cytologic, and hormonal-metabolic parameters (blood estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), glucose, and cholesterol by radioimmunoassay, enzyme immune assay, or enzyme-colorimetric methods; tumor progesterone receptors by ligand-binding assay; and aromatase activity by 3H-water release assay) were evaluated before and after treatment. RESULTS: Treatment was well-tolerated in all patients. In two patients, pain relief in the lower part of the belly and/or decrease in intensity of uterine discharge was reported. In the three cases, substantial decreases in endometrial M-echo (ultrasound) signal were noted; the mean value of this parameter after treatment was 31.1% lower than before treatment. Blood estradiol concentration decreased by an average of 37.8% after letrozole therapy, and tumor progesterone receptor levels and aromatase activity decreased by 34.4 and 17.5%, respectively. Treatment with letrozole did not influence surgery. CONCLUSIONS: These data show that short-term treatment with letrozole in the neoadjuvant setting resulted in some positive clinical changes. Longer-term and larger-scale trials of neoadjuvant letrozole in endometrial cancer are warranted.

***BajanBastard*** · 01-07-2005, 10:09 PM

Progesterone and estrogen also work together to cause mammary gland stimulation.(deca gyno) so dealing with estrogen WILL PREVENT DECA/FINA GYNO.

Endocrinology, Vol 103, 186-192, Copyright © 1978 by Endocrine Society

ARTICLES

Progesterone is not essential to the differentiative potential of mammary epithelium in the male mouse
CS Freeman and YJ Topper

In pursuit of a model system in which to determine whether or not exposure to progesterone is necessary for mammary epithelial cells to develop their differentiative potential, we explored hormone-dependent growth of the mammary epithelial rudiment in adult male mice. Initiation of the formation of ductal cells can be effected by administration of estradiol in the absence of endogenous progesterone and glucocorticoid using adrenalectomized-castrated animals. The resulting epithelium contains three times more lactose synthetase activity per epithelial cell than that in midpregnant mice. The blood spermidine level in these doubly operated animals was similar to the concentration of spermidine required to substitute effectively for glucocorticoid during mammary differentiation in vitro. It is suggested that spermidine can partially supplant glucocorticoid in vivo in milk protein synthesis. We also concluded that, unlike other secondary sex tissues, mammary cells do not require exposure to progesterone during their ontogeny in order to realize their differentiative potential. The positive role of this steroid in mammary development is apparently limited to its effect on the formation of alveolar structures.